ArticleNPJ precision oncology2026
Adipocyte-driven STAT3-ANGPT2-PTGIS axis promotes cutaneous metastasis in breast cancer and represents a targetable pathway.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous metastatic breast cancer (CMBC) exhibits aggressive behavior driven by tumor adaptation to the skin microenvironment, yet research specifically addressing breast cancer metastasis to the skin remains limited, representing a significant unmet clinical need. In this study, transcriptomic profiling, functional assays, and mouse models revealed that CMBC is associated with poor prognosis and upregulation of angiogenesis, inflammatory signaling, and lipid metabolism, particularly arachidonic and linoleic acid pathways. Adipocyte-derived signals enhanced cutaneous metastasis through STAT3 activation, leading to increased Angpt2, Vegfc, and Ptgis expression. Pharmacologic inhibition of STAT3 suppressed metastasis in vitro and in vivo. Elevated STAT3, ANGPT2, and PTGIS levels correlated with reduced progression-free and disease-free survival. These findings highlight STAT3-mediated signaling and metabolic reprogramming as key drivers of CMBC progression and suggest a promising therapeutic target for this understudied and clinically challenging condition.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.